Robin Shah: Communicating With Patients About the Value of Biosimilars

Robin Shah, chief commercial officer of OneOncology, addresses how practices can communicate the value of biosimilars to patients.
November 08, 2019


So the way that we think about communicating with patients in general about this whole cost of care is being transparent through the initial consult process. So in all of our clinics, we have financial counselors that work with all of our practices and patients so they truly understand what treatment they're getting, then what the cost of that care is. And with biosimilars being introduced, we can now show and represent that the patients are getting the same outcomes, with the lower cost of care, with the agents that are available.


Click here to view Biosimilars CME Activities

Click here to view Biosimilars PTCE Activities

Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars® is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2020 Intellisphere, LLC. All Rights Reserved.